Shenzhen Mindray Bio-Medical Electronics Co (300760) Fair Value & Analysis

Healthcare · CN · Market cap 181B CNY

A solid business, currently priced close to our fair value.

What matters now

• The price sits close to our fair value, market and models broadly agree here, little valuation tension.
• Our model range runs from ¥110.72 (bear) to ¥181.85 (bull), base ¥147.63. The closer the price sits to the lower half, the larger the margin of safety.
• Quality 63/100 (solid quality) with medium evidence: read the verdict with care.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 18, 2026.

How to read this chart

60‑month range ¥133.98 – ¥448.86 · fair‑value band ¥110.72 – ¥181.85 · the ¥149.75 price screens above the ¥147.63 fair value. Dashed = 300-day average. As of Jul 18, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Shenzhen Mindray Bio-Medical Electronics Co (300760) currently trades at ¥149.75, while our model-based Fair Value estimate is ¥147.63, implying the stock looks roughly 1.4% fairly valued today. We read business quality at 63/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).

Over the trailing twelve months, Shenzhen Mindray Bio-Medical Electronics Co generated revenue of 33.4B CNY at a net margin of 23.5%. Revenue grew 1.4% year over year. It earns a return on equity of 18.5%. The balance sheet holds a net cash position of 16.5B CNY. Fundamentals as of Jul 18, 2026

Our scenario range runs from ¥110.72 (bear case) to ¥181.85 (bull case); at ¥149.75, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 40% below its 52-week high and 6% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -26% fair-value upside, at -1%, 300760 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: DCF Models (¥175.05) versus Asset-Based (¥21.05). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. provides medical devices and solutions in China and internationally. The company offers various products, including patient monitoring, ultrasound, radiology, AED, defibrillation system, anesthesia, CLIA, chemistry, hematology, ventilators, electrocardiograph, endoscope camera system, operating tables, …

Full company description

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. provides medical devices and solutions in China and internationally. The company offers various products, including patient monitoring, ultrasound, radiology, AED, defibrillation system, anesthesia, CLIA, chemistry, hematology, ventilators, electrocardiograph, endoscope camera system, operating tables, surgical lights, medical supply units, accessories, infusion system, orthopedics, IT Products, cardiovascular intervention, animal medical, and OEM products. It also provides various solutions, such as M-connect IT, M-connect ER, M-connect ICU, M-connect OR, and M-connect CCU solutions; advanced patient monitoring and intelligent ventilation, emergency ultrasound solutions, and fast defibrillation; customized pendant and critical care ultrasound solutions; precise anesthesia, minimally invasive surgery, infusion system, surgical lights, and anesthesia ultrasound solutions; laboratory diagnostics, medical imaging, and cybersecurity solutions. The company was founded in 1991 and is headquartered in Shenzhen, the People's Republic of China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Shenzhen Mindray Bio-Medical Electronics Co reported revenue of ¥33.3B in FY2025 versus ¥25.3B in FY2021, a compound +7.1%/yr. Reported net income was ¥8.1B in FY2025, compounding +0.4%/yr from FY2021.

Watch 300760: get an alert when its fair value changes →

Peer Group

Medical Devices · 350 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Medical Devices median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Insider activity: 40/100

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 18, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.